180 related articles for article (PubMed ID: 28515254)
1. NCCN Debuts New Guidelines for Myeloproliferative Neoplasms.
Mesa RA
J Natl Compr Canc Netw; 2017 May; 15(5S):720-722. PubMed ID: 28515254
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
Naqvi K; Daver N; Pemmaraju N; Bose P; Garcia-Manero G; Cortes J; Kantarjian HM; Verstovsek S
Leuk Lymphoma; 2017 Apr; 58(4):866-871. PubMed ID: 27494751
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Soret J; Kiladjian JJ
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.
Tremblay D; King A; Li L; Moshier E; Coltoff A; Koshy A; Kremyanskaya M; Hoffman R; Mauro MJ; Rampal RK; Mascarenhas J
Leuk Lymphoma; 2020 Mar; 61(3):660-667. PubMed ID: 31711337
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
Mesa RA
IDrugs; 2010 Jun; 13(6):394-403. PubMed ID: 20506062
[TBL] [Abstract][Full Text] [Related]
6. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Eliaçık E; Işık A; Aksu S; Üner A; Büyükaşık Y; Sayınalp N; Göker H; Özcebe OI; Haznedaroğlu İC
Turk J Haematol; 2015 Jun; 32(2):163-7. PubMed ID: 26316485
[TBL] [Abstract][Full Text] [Related]
7. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T; Tefferi A; Vannucchi AM; Passamonti F; Silver RT; Hoffman R; Verstovsek S; Mesa R; Kiladjian JJ; Hehlmann R; Reiter A; Cervantes F; Harrison C; Mc Mullin MF; Hasselbalch HC; Koschmieder S; Marchetti M; Bacigalupo A; Finazzi G; Kroeger N; Griesshammer M; Birgegard G; Barosi G
Leukemia; 2018 May; 32(5):1057-1069. PubMed ID: 29515238
[TBL] [Abstract][Full Text] [Related]
8. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
Mesa RA; Jamieson C; Bhatia R; Deininger MW; Fletcher CD; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; McMahon B; Mohan SR; Oh S; Padron E; Papadantonakis N; Pancari P; Podoltsev N; Rampal R; Ranheim E; Reddy V; Rein LAM; Scott B; Snyder DS; Stein BL; Talpaz M; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2017 Oct; 15(10):1193-1207. PubMed ID: 28982745
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
[TBL] [Abstract][Full Text] [Related]
10. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):277-86. PubMed ID: 25696867
[TBL] [Abstract][Full Text] [Related]
11. Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.
Barosi G; Lupo L; Rosti V
Curr Hematol Malig Rep; 2012 Mar; 7(1):50-6. PubMed ID: 22278747
[TBL] [Abstract][Full Text] [Related]
12. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Rosenthal A; Mesa RA
Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
15. Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.
Koshiishi M; Sueki Y; Kawashima I; Nakajima K; Mitsumori T; Kirito K
Intern Med; 2017 Sep; 56(17):2335-2338. PubMed ID: 28794380
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Sapre M; Tremblay D; Wilck E; James A; Leiter A; Coltoff A; Koshy AG; Kremyanskaya M; Hoffman R; Mascarenhas JO; Gallagher EJ
Sci Rep; 2019 Nov; 9(1):16609. PubMed ID: 31719581
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
18. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
19. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
Bose P; Verstovsek S
J Natl Compr Canc Netw; 2016 Dec; 14(12):1613-1624. PubMed ID: 27956543
[TBL] [Abstract][Full Text] [Related]
20. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
Mesa RA; Scherber RM; Geyer HL
Leuk Lymphoma; 2015 Jul; 56(7):1989-99. PubMed ID: 25644746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]